259 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
in 2023, with the change due to the timing of customer orders. Contract revenue and other income was $2.7 million for the first quarter of 2024
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
to the timing of customer orders. There were no Captisol sales related to COVID-19 in 2023, compared with $88.1 million in 2022. Contract revenue for 2023
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
quarter of 2023, compared with $3.6 million for the same period in 2022, with the increase due to the timing of customer orders. There were no Captisol … in 2022. The difference in sales was due to the timing of customer orders. There were no Captisol sales related to COVID-19 for the nine months ended
8-K
EX-99.1
axmyc57
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
enkws8 zb6nuist
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
gkcmdsjtr6mlxmw
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
xlkuwytjynkcpdb
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
9f5mmqdg4vnxpi19z
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
S-3ASR
EX-1.2
72no8nk7stkf
30 Sep 22
Automatic shelf registration
4:17pm
8-K
EX-99.1
ocnezely
8 Aug 22
Ligand Reports Second Quarter 2022 Financial Results
4:06pm
425
5gb4qo tich1a65zr4b
5 May 22
Business combination disclosure
7:30am
8-K
EX-99.1
dlqx28db
4 May 22
Ligand Reports First Quarter 2022 Financial Results
4:03pm
425
rdw01sd6m3x8y
24 Mar 22
Business combination disclosure
9:09am